Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical calcipotriene for morphea/linear scleroderma

B B Cunningham1, I D Landells, C Langman

  • 1Department of Pediatrics, Northwestern University Medical School, Chicago, Illinois, USA.

Journal of the American Academy of Dermatology
|August 15, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression of skin-limited pediatric-onset discoid lupus erythematosus to diagnosis of systemic lupus erythematosus: results of a multicenter, retrospective cohort study.

Journal of the American Academy of Dermatology·2026
Same author

Skin pain and sleep quality numeric rating scales for children aged 6 months to 5 years with atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Harmonizing body surface area assessments between the Eczema Area and Severity Index, SCORing Atopic Dermatitis, and handprint methods utilizing one shared measurement-A proposal to improve efficiency and reduce error in atopic dermatitis trials.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus.

Orphanet journal of rare diseases·2023
Same author

Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders.

Skin health and disease·2022
Same author

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same journal

Hypoactive Sexual Desire Disorder in Menopausal Women: Dermatologic Implications of Antiandrogen and Testosterone Therapy.

Journal of the American Academy of Dermatology·2026
Same journal

Incise parallel, section perpendicular to the dermatoglyphs for diagnosis of acral melanocytic lesions-A comment on Thakker et al.

Journal of the American Academy of Dermatology·2026
Same journal

Response to Xue et al, "Defining super-responders is not the same as predicting rituximab response in pemphigus".

Journal of the American Academy of Dermatology·2026
Same journal

Comment on Nie et al. (2026) 'Suicidality Reports in Acne Patients Treated with Isotretinoin and Concomitant Antidepressants: A Descriptive Analysis of FDA Adverse Event Reporting System Data'.

Journal of the American Academy of Dermatology·2026
Same journal

Defining super-responders is not the same as predicting rituximab response in pemphigus.

Journal of the American Academy of Dermatology·2026
Same journal

Eosinophilic fasciitis induced by checkpoint inhibitors: a retrospective multicenter case-series, comparison with eosinophilic fasciitis unrelated to checkpoint inhibition and literature review.

Journal of the American Academy of Dermatology·2026
See all related articles

Topical calcipotriene 0.005% ointment showed significant improvement in morphea and linear scleroderma patients. This vitamin D analog may be an effective treatment for localized scleroderma.

Area of Science:

  • Dermatology
  • Rheumatology
  • Endocrinology

Background:

  • Morphea and linear scleroderma present with erythema, induration, telangiectasia, and dyspigmentation, lacking universally effective treatments.
  • Oral calcitriol has shown benefits for localized and extensive scleroderma, but topical calcipotriene's efficacy remains unreported.

Observation:

  • An open-label study evaluated topical calcipotriene 0.005% ointment in 12 patients (aged 12-38) with active morphea or linear scleroderma.
  • Patients applied the ointment twice daily under occlusion for 3 months, having previously failed potent topical corticosteroids and/or systemic therapies.

Findings:

  • All 12 patients experienced statistically significant improvement in all evaluated features over the 3-month trial.
  • No adverse effects were reported, and laboratory monitoring of mineral metabolism showed no abnormalities.

Related Experiment Videos

Implications:

  • Topical calcipotriene 0.005% ointment demonstrates potential as an effective treatment for localized scleroderma.
  • Further confirmation through double-blind, placebo-controlled studies is warranted to validate these findings.